Suppr超能文献

治疗性、人源化单克隆抗体对鲍曼不动杆菌具有广泛的结合和保护效力。

Therapeutic, Humanized Monoclonal Antibody Exhibits Broad Binding and Protective Efficacy against Acinetobacter baumannii.

机构信息

Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.

Los Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA.

出版信息

Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0008623. doi: 10.1128/aac.00086-23. Epub 2023 Feb 28.

Abstract

Acinetobacter baumannii is an extremely drug-resistant pathogen necessitating the development of new therapies. We seek to generate a cocktail of monoclonal antibodies (MAbs) that can target the full diversity of A. baumannii isolates. We have newly identified the antibody MAb5. Here, we demonstrate that MAb5 has broad binding against U.S. ( = 300) and international ( = 250) isolates (72.24% and 28.76%, respectively), likely targets O-antigen capsular carbohydrates, and exhibits protective efficacy .

摘要

鲍曼不动杆菌是一种具有极强耐药性的病原体,需要开发新的治疗方法。我们试图生成一种可以针对鲍曼不动杆菌分离株的全部多样性的单克隆抗体(MAb)混合物。我们新鉴定出了抗体 MAb5。在这里,我们证明 MAb5 对美国( = 300)和国际( = 250)分离株具有广泛的结合活性(分别为 72.24%和 28.76%),可能靶向 O-抗原荚膜碳水化合物,并表现出保护效力。

相似文献

10
Clinical implications of glycoproteomics for Acinetobacter baumannii.鲍曼不动杆菌糖蛋白质组学的临床意义
Expert Rev Proteomics. 2015 Feb;12(1):1-3. doi: 10.1586/14789450.2015.987756. Epub 2014 Dec 11.

本文引用的文献

3
Monoclonal Antibody Therapy against .针对 的单克隆抗体疗法。
Infect Immun. 2021 Sep 16;89(10):e0016221. doi: 10.1128/IAI.00162-21. Epub 2021 Jul 26.
9
Treatment of Acinetobacter infections.治疗不动杆菌感染。
Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验